Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials

BACKGROUND: Whether erlotinib plus tivantinib (ET) can achieve better clinical benefits than erlotinib plus placebo (EP) among participants with previously treated advanced non-small-cell lung cancer (NSCLC) is still disputed. We conducted a meta-analysis to evaluate the anticancer efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Huan, Wang, Li, Chen, Xinling, Zhang, Shujuan, Yi, Fengming, Wei, Yiping, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313549/
https://www.ncbi.nlm.nih.gov/pubmed/32569187
http://dx.doi.org/10.1097/MD.0000000000020596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313549/
https://www.ncbi.nlm.nih.gov/pubmed/32569187
http://dx.doi.org/10.1097/MD.0000000000020596

Ejemplares similares